Assessment of the impact of national breast cancer screening program in achieving downstaging of breast cancer and improving quality of life of breast cancer patients in Morocco

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN16276576

Enrollment

3000

Registered

2019-07-16

Start date

2019-05-01

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer Cancer Malignant neoplasm of breast

Interventions

Before initiation of treatment, the patients will be interviewed by trained staff using a questionnaire to document the following information: basic personal data (contact details, age, residence, edu

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Women registered with the histopathology diagnosis of breast cancer at the designated cancer centre(s) during the study period

Exclusion criteria

Exclusion criteria: Women in whom the final histopathology diagnosis will be benign disease; recurrent breast cancers

Design outcomes

Primary

Measure	Time frame
1. Mean duration between detection by CBE (in the patients referred through screening program) or onset of symptoms (in the self-reported group) and date of registration at the cancer hospital (access delay); mean duration between registration and the confirmation of diagnosis (diagnosis delay); and mean duration between confirmation of diagnosis and onset of treatment (treatment delay): estimated using the data collected by a questionnaire which includes date of CBE, date of onset of symptoms, date registration at cancer center, date of confirmation of diagnosis and date of treatment onset. 2. Distribution of breast cancer stage (clinical TNM and pathology TNM), lymph node status, IHC status and type of treatment by the groups (screen-detected and self-reported breast cancer cases): reported using the data collected by a questionnaire which was designed to capture breast cancer stage (clinical TNM and pathology TNM), lymph node status, immunohistochemistry status and type of treatment at the time of the recruitment and the initiation of treatment. 3. Rate of breast preservation surgeries by groups (screen-detected and self-reported breast cancer cases): calculated using the data collected by a questionnaire which was designed to capture the type of surgery at the time of initiation of treatment. 4. Treatment response rate by groups (screen-detected and self-reported breast cancer cases): calculated using the data collected by a questionnaire which was designed to capture the treatment response one year after completion of treatment. 5. Functional dimensions and symptoms scores on QOL study and improvement between pre- and post-treatment scores by groups (screen-detected and self-reported breast cancer cases): measured using the QLQ-C30 and the EORTC QLQ-BR23 questionnaires of the European Organization for Research and Treatment of Cancer (EORTC) before the initiation of any treatment, 1 month after completion of definitive treatment and 1 year after completion of t	—

Measure

Time frame

1. Mean duration between detection by CBE (in the patients referred through screening program) or onset of symptoms (in the self-reported group) and date of registration at the cancer hospital (access delay); mean duration between registration and the confirmation of diagnosis (diagnosis delay); and mean duration between confirmation of diagnosis and onset of treatment (treatment delay): estimated using the data collected by a questionnaire which includes date of CBE, date of onset of symptoms, date registration at cancer center, date of confirmation of diagnosis and date of treatment onset. 2. Distribution of breast cancer stage (clinical TNM and pathology TNM), lymph node status, IHC status and type of treatment by the groups (screen-detected and self-reported breast cancer cases): reported using the data collected by a questionnaire which was designed to capture breast cancer stage (clinical TNM and pathology TNM), lymph node status, immunohistochemistry status and type of treatment at the time of the recruitment and the initiation of treatment. 3. Rate of breast preservation surgeries by groups (screen-detected and self-reported breast cancer cases): calculated using the data collected by a questionnaire which was designed to capture the type of surgery at the time of initiation of treatment. 4. Treatment response rate by groups (screen-detected and self-reported breast cancer cases): calculated using the data collected by a questionnaire which was designed to capture the treatment response one year after completion of treatment. 5. Functional dimensions and symptoms scores on QOL study and improvement between pre- and post-treatment scores by groups (screen-detected and self-reported breast cancer cases): measured using the QLQ-C30 and the EORTC QLQ-BR23 questionnaires of the European Organization for Research and Treatment of Cancer (EORTC) before the initiation of any treatment, 1 month after completion of definitive treatment and 1 year after completion of t

—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

Morocco

Contacts

Public ContactYoussef Khazraji Chami

youssef.chami@flsc.ma+212 (0)661614261

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 7, 2026